WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative pathogens, today announced that it has appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin will provide strategic leadership with the board, working closely with management as the Company seeks to advance its market-leading antibiotics franchise.
